Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Jan 19, 2026; 15(1): 113080
Published online Jan 19, 2026. doi: 10.5497/wjp.v15.i1.113080

Full Size Figure Download Figure

Figure 1 The screening process. GCGR: Glucagon receptor; GLP-1R: Glucagon-like peptide-1 receptor.

Citation: Deng CX, Chen ZM, Tang YX, Xi ZX, Wang SY, Wu HY, Xu B, Xu TC. Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors. World J Pharmacol 2026; 15(1): 113080
URL: https://www.wjgnet.com/2220-3192/full/v15/i1/113080.htm
DOI: https://dx.doi.org/10.5497/wjp.v15.i1.113080

Deng CX, Chen ZM, Tang YX, Xi ZX, Wang SY, Wu HY, Xu B, Xu TC. Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors. World J Pharmacol 2026; 15(1): 113080 [DOI: 10.5497/wjp.v15.i1.113080]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.